Laurel Wealth Advisors (North Carolina)’s Nektar Therapeutics NKTR Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-20	Closed	-$4K	–	692
2021 Q4	$4K	Hold	20	–	–	﹤0.01%	510
2021 Q3	$5K	Hold	20	–	–	﹤0.01%	484
2021 Q2	$5K	Hold	20	–	–	﹤0.01%	549
2021 Q1	$6K	Hold	20	–	–	﹤0.01%	475
2020 Q4	$5K	Sell	20 -60	-75%	-$15.5K	﹤0.01%	478
2020 Q3	$20K	Hold	80	–	–	0.01%	315
2020 Q2	$28K	Hold	80	–	–	0.01%	282
2020 Q1	$21K	Hold	80	–	–	0.01%	289
2019 Q4	$26K	Hold	80	–	–	0.01%	304
2019 Q3	$22K	Hold	80	–	–	0.01%	313
2019 Q2	$43K	Hold	80	–	–	0.02%	249
2019 Q1	$40K	Hold	80	–	–	0.01%	249
2018 Q4	$39K	Buy	+80	New	+$48.3K	0.02%	235

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s NKTR Position: Q1 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of Nektar Therapeutics (NKTR) in Q1 2022, closing a stake of 20 shares — an estimated $4K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in NKTR in Q4 2018 and held it in 13 quarters. The position peaked at $43K in Q2 2019. 239 funds tracked by Wall St. Rank hold NKTR as of Q1 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining Nektar Therapeutics position as of Q1 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 20 Nektar Therapeutics shares in Q1 2022, an estimated $4K.
Laurel Wealth Advisors (North Carolina) first reported a position in Nektar Therapeutics in Q4 2018 and held it in 13 quarters.
Laurel Wealth Advisors (North Carolina)'s Nektar Therapeutics position peaked at $43K in Q2 2019.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q1 2022, filed 2 May 2022.